Mar. 23, 2016

Keystone Nano is pleased to announce that the National Cancer Institute (NCI) has selected the company to participate in BIO 2016, being held in San Francisco in June. Keystone Nano will participate in the bio-partnering program and the exhibit as a part of the NCI delegation of emerging cancer companies.
BIO’s International Convention has been a leading meeting worldwide for biotechnology and pharmaceutical companies for more than two decades. The meeting features tens of thousands of participants seeking to build cooperative business opportunities.

Keystone Nano is an emerging biopharmaceutical company developing three independent but interrelated nanotechnology therapeutic platforms for the treatment of cancer and infectious disease:
Ceramide Nanoliposome - a novel therapy that will begin human testing in August 2016 with a $2.0 million grant from the National Cancer Institute.
Photo Immuno Nano Therapy -- a non-toxic therapy for the treatment of cancer that combines immune up regulation and photo therapy utilizing NanoJackets. Keystone’s NanoJackets are biocompatible calcium phosphate nanoparticles that protect the active ingredient in serum and deliver it to the interior of the cell. They may be actively or passively targeted to specific cell types.

RNA-NanoJackets -- New therapies for the treatment of cancer and infectious disease using siRNA, mRNA and miRNA via NanoJackets.
At BIO, KN will be seeking partners interested in Ceramide NanoLiposome and the improved delivery of RNA as well as other anti-cancer compounds using NanoJackets.